СLINICAL INTERRELATIONS OF ARTERIAL HYPERTENSION AND GOUT
- Authors: Khalfina TN1, Maksudova AN1
-
Affiliations:
- Issue: No 6 (2011)
- Pages: 42-44
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/246016
- ID: 246016
Cite item
Full Text
Abstract
Aim. Characteristics of interrelations of arterial hypertension, uric acid metabolism parameters and severity of gout.
Methods. 65 patients with gout without chronic kidney disease were included into the study; 50 of them had arterial hypertension. Standard biochemical parameters of blood and urine, characterizing uric acid metabolism, were analyzed.
Results. Hypertensive patients had more severe gout (severity index 3,6 [2,7; 5] vs 2,2 [2; 3]) and higher levels of uricemia (555[472,5; 625,5] vs 454 [355;504] mcmol/l). Patients with arterial hypertension III stage had highest levels of uricemia and the most severe gout.
Conclusion. Uricemia and severity of gout increased according to the enhancement of arterial hypertension.
Methods. 65 patients with gout without chronic kidney disease were included into the study; 50 of them had arterial hypertension. Standard biochemical parameters of blood and urine, characterizing uric acid metabolism, were analyzed.
Results. Hypertensive patients had more severe gout (severity index 3,6 [2,7; 5] vs 2,2 [2; 3]) and higher levels of uricemia (555[472,5; 625,5] vs 454 [355;504] mcmol/l). Patients with arterial hypertension III stage had highest levels of uricemia and the most severe gout.
Conclusion. Uricemia and severity of gout increased according to the enhancement of arterial hypertension.
Keywords
References
- Feig D. I., Kang D. H., Johnson R. J., Uric acid and cardiovascular risk. N Engl J Med 2008; 359 (17): 1811-1821.
- Perlstein T. S., Gumieniak O., Williams G.H. et al. Uric acid and the development of hypertension: The Normative Aging Study. Hypertension. 2006; 48:1031-1036.
- Кобалава Ж.Д., Толкачева В.В., Караулова Ю.Л. Мочевая кислота - маркер и/или новый фактор риска развития сердечно-сосудистых осложнений? РМЖ 2002; 10: 431-436.
- Gaffo A. L., Edwards N. L., Saag K. G. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? Arthritis Research & Therapy 2009; 11(4):240
- Логинова Т.К., Шостак Н.А., Хоменко В.В. Эволюция представлений о подагре. Подагра и метаболический синдром. Клин. Геронтология 2005; 4: 22-25.
- Johnson R. J., Kang D.H., l Feig D., Kivlighn S and all. Is There a Pathogenetic Role for Uric Acid in Hypertension and Cardiovascular and Renal Disease? Hypertension 2003; 41:1183-1190.
- Мухин Н.А., Балкаров И.М., Бритов А.Н. и др. Тубулоинтерстициальный нефрит и артериальная гипертензия - клиническое и популяционное значение. Тер. арх. 97; 6: 5-10.
- Ильина А.Е., Барскова В.Г., Насонов Е.Л. Подагра, гиперурикемия и кардиоваскулярный риск. Научно-практич. ревматол 2009; 1: 56-62.
- Cappucio FP, Strazzullo P, Farinaro E, et al. Uric acid metabolism and tubular sodium handling. Results from apopulation-based study. JAMA 1993; 270(3): 354-359
- Mazzali M., Kanellis J., Han L. et al.. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. AJP-Renal Physiol 2002; 10: 991-997.
- Perlstein T. S., Gumieniak O., Hopkins P. N. et al. Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int/ 2004; 66: 1465-1470.
- Ильиных Е. В. Факторы риска развития кардиоваскулярных заболеваний у больных подагрой. Автореф. дис. канд. мед. наук. М. 2006. 21
- Якунина И.А. Индекс тяжести подагры: Автореф. дис. канд. мед. наук. М., 2006: 24.
- Мухин Н.А. Гиперурикемия, артериальная гипертензия и хроническая болезнь почек почек: интерпретация взаимосвязи и стратегия действий. Клин. нефр. 2009;4:4-11.
- Шюк O. Функциональные исследования почек. Прага. Авиценум 1975. 218-219.
- Кудаева Ф.М., Барскова В.Г., Гордеев А.В. Современные представления о факторах, обуславливающих поражение почек при подагре. Тер. архив 2005; 5: 90-95.
- Leyvat F., Anker S., Swanf J. W. et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur. Heart J. 1997; 18: 858-865.
Supplementary files
